Who is in charge of the Jianghu: 32 domestic top selling drugs

Source: in "who holds the bull's ear: 14 domestic sales of over 2 billion best-selling drugs" on March 17, 2016, pharmaceutical economics Daily, the author summarized the preferences and success factors of the layout of foreign enterprises, especially the situation of the unification of foreign enterprises in the field of diabetes medicine What about anti-tumor drugs? China is also a country with a high incidence of cancer Don't foreign enterprises value this field? For this outstanding case, this article will do an answer Of course, this article is not limited to the analysis of anti-tumor drugs Based on the data of annual sales between 1 billion and 2 billion yuan, this paper makes a summary of those drugs whose sales share of foreign enterprises exceeds 50%, analyzes the layout preferences of foreign enterprises at this level and the details we should pay attention to 1 Category of esomeprazole: anti ulcer drug enterprise and share: AstraZeneca, 100% esomeprazole trade name is "nexin", which belongs to proton pump inhibitor, is the S-isomer of omeprazole, listed in 2000 From 2006 to 2011, the annual sales performance of Nexium was about 5 billion US dollars, and the patent expired in 2014 At present, only Chongqing Laimei holds the approval document of the drug Although there are bidding information in Fujian, Shanghai and other places, the market data may not be very detailed due to data collection 2 Categories of metformin, insulin glargine and repaglinide: diabetes drug enterprises and shares: metformin is a classic old drug for treating diabetes Data shows that hundreds of enterprises in China produce this product, including ordinary and slow-release tablets and capsules The total share of local products is less than 30% The author looks up the bidding price of each province Although the bidding price of the original research enterprise is higher than that of the generic medicine, it is still acceptable It is speculated that the reason why the original research drug won the market is due to its good technology and excellent quality assurance Insulin glargine, the trade name "when it comes", is Sanofi's super heavyweight drug and a regular on the top 25 list of the world's best-selling drugs Due to the expiration of the patent in February 2015, although its sales reached 6.39 billion euros in 2015, it was down 10.8% year on year Its sales decline was mainly from the US market, down as much as 20.5% However, it has strong growth in emerging markets, including China, with a growth rate of 17.3% Last year, China approved the listing of the generic drugs, and it will take time to expand the market Novo Nordisk's regrainet was approved by the FDA on December 22, 1997 The market was jointly developed by Novo Nordisk and bringer Ingelheim It was the first drug to regulate blood sugar during meals It entered the Chinese market in 2000 As a new type of short-term insulin secretion and hypoglycemic drug, its hypoglycemic effect is 10-20 times stronger than that of youjiangtang It stimulates the first phase of insulin secretion, has a fast effect and a short duration, which is conducive to reducing postprandial blood sugar At present, the patents of reggenet in the United States, China and Germany have expired Several enterprises in China, such as Jiangsu Haosen, have approval documents for generic drugs The price advantage should be conducive to the expansion of local products market 3 Mecobalamin category: anti anemia drugs and other enterprises and shares: Weicai, 56% Mecobalamin is an endogenous coenzyme B12, which is suitable for the treatment of peripheral neuropathy and megaloblastic anemia caused by vitamin B12 deficiency Mecobalamin is researched and developed by Japanese sanitary materials, and entered China in 2002 At present, there are dozens of domestic enterprises producing Mecobalamin In May 2015, Weicai submitted the application of mecobalamin as a new drug for ALS (amyotrophic lateral sclerosis) treatment in Japan Whether domestic enterprises follow up or not remains to be seen 4 Type of peritoneal dialysate: plasma substitute enterprise and share: Baite, 91% peritoneal dialysate is a clear liquid containing sodium, chlorine, calcium, magnesium and glucose, which is commonly used in acute and chronic renal failure Although in many countries and regions, peritoneal dialysis has been listed as the first choice of renal replacement therapy for patients with chronic renal failure, there is still a big gap between China and foreign countries in terms of relevant technical level 5 Metoprolol category: beta blocker enterprise and share: AstraZeneca, 95% metoprolol mainly reduces cardiac excitability, cardiac output and myocardial oxygen consumption, alleviates angina pectoris, and reduces hypotension by reducing renin release Metoprolol tartrate is a new molecular entity approved by FDA in 1978, and then metoprolol succinate, as the second generation of "lol", has smaller side effects than the first generation At present, the best-selling is AstraZeneca's metoprolol succinate sustained-release dosage form, such domestic products have not been listed Metoprolol tartrate is competitive because of its many manufacturers and dosage forms, and its market is dominated by metoprolol succinate 6 Nifedipine category: calcium channel blocker enterprise and share: Bayer, 82% nifedipine belongs to dihydropyridine, which is clinically used for anti angina and hypertension Bayer product "baixintong" is a controlled-release preparation of nifedipine Nifedipine is a new molecular entity approved by FDA in 1981, and its controlled-release preparation was approved in 1989 It is a classic old drug At present, many sustained-release and controlled-release preparations have been listed in China However, due to the close relationship between the release degree of sustained-release and controlled-release preparations, process control and excipients, domestic enterprises are still in a follow-up state in the research of innovative dosage forms, but it is not a one-day success to break the advantages of foreign enterprises, and it needs patience 7 Valsartan, irbesartan and losartan: the enterprise and share of angiotensin: the latter belongs to a relatively new antihypertensive drug, which is increasingly favored by patients due to its good tolerance and significant renal protection Valsartan, irbesartan and losartan are commonly used antihypertensive drugs Losartan is the first sartan drug in the world It is a new molecular entity approved by FDA in 1995, with the trade name of "kosoa"; irbesartan was approved in 1997, as a product of Sanofi Aventis, with the trade name of "ambowei"; valsartan was approved by FDA in 1996 At present, the three sartans are produced by many enterprises at home and abroad In recent years, the best selling sartans in the global market are "Daiwen" The sales volume of sartans and its compound preparation "fudaiwen" was once a member of the top 25 best-selling drugs in the world With the expiration of the patent in 2012, the scenery of the original research has disappeared, but it is still popular in China 8 Octreotide category: hypothalamus pituitary anterior hormone enterprise and share: Novartis, 54% octreotide is an eight peptide derivative of synthetic natural somatostatin, which is clinically used in acromegaly, gastrointestinal and pancreatic endocrine tumors First approved in New Zealand in 1988 and approved by FDA in the same year, it is a new molecular entity with priority review qualification, and then listed in other regions of the world In 1994, octreotide injection was introduced into China, and in 2003, microspheres for injection of long-acting preparations were also listed Due to the large price difference between the two, the market is dominated by regular effect preparations At present, the combined market share of Novartis and octreotide is close to 60% 9 Methylprednisolone category: enterprise and share of systemic corticosteroids: Pfizer, 79% methylprednisolone, also known as methylprednisolone, is a medium effect glucocorticoid, which is clinically used for life-threatening adjuvant treatment, as well as for severe systemic lupus erythematosus and lupus nephritis, renal transplant rejection, etc Methylprednisolone is a classic drug approved in the 1950s At present, methylprednisolone sodium succinate injection is the main market Due to the wide clinical use of drugs, it has been ranked first in the sales of such drugs for many years Although there are many domestic production approvals, the market has been dominated by Pfizer for a long time 10 Fluconazole category: antifungal drug enterprise and share: Pfizer, 90% fluconazole belongs to triazole broad-spectrum antifungal drug, trade name "Dafukang", which is Pfizer's original research product It is a new molecular entity approved by FDA in 1990, and the imitators from all countries are welcome after the patent expires in 2004 China used the product earlier The product has a variety of dosage forms, including tablets, capsules, injections, etc Although there are hundreds of enterprises in China, the market share has not been high According to provincial bidding data, except for the original research drugs, the "price war" of domestic enterprises is very hot, which should be the key reason 11 Types of ceftriaxone and vancomycin: anti bacterial enterprises and shares: ceftriaxone belongs to the third generation cephalosporin, which is characterized by stronger anti gram negative bacteria than the second generation, and stable for broad-spectrum β - lactamase Ceftriaxone has a long half-life and can be administered once a day It is commonly used in lower respiratory tract infection and urinary tract infection Ceftriaxone is a new molecular entity approved by FDA in 1984 At present, the patent has expired There are many generic drugs in the world Roche and Pansheng in Taiwan have an absolute advantage in the domestic market The reason is the same as the result of the above bidding price Vancomycin belongs to polypeptide antibiotics As the pioneer of this kind of antibiotics, vancomycin has strong antibacterial effect on all kinds of Gram-positive bacteria It is a classic old medicine approved in the 1960s, and it has been produced in China earlier, and norvancomycin has also been first discovered in China, but so far only a few enterprises have approval documents for this product 12 Lamivudine category: antiviral enterprise and share: Glaxo, 87% lamivudine is a nucleoside reverse transcriptase inhibitor, which is a azido thymidine analogue, approved by FDA in 1998 for the treatment of chronic hepatitis B Its active form is lamivudine triphosphate As a competitive inhibitor of DCTP, it can inhibit the activity of viral reverse transcriptase, terminate the extension of viral DNA chain and inhibit the synthesis of viral DNA CFDA approved the drug to be imported mainly for hepatitis B treatment, with the Chinese trade name of "hepudine", which was officially sold in China in 1999 At present, more than ten domestic enterprises have produced this product 13 Capecitabine, rituximab, imatinib, trastuzumab category: antineoplastic enterprises and shares: Capecitabine is an anti metabolism anti-tumor drug, which belongs to the inhibitor of deoxythymidylate synthetase It is used in the treatment of advanced primary or metastatic breast cancer, colorectal cancer and gastric cancer Capecitabine is a new molecular entity of Roche approved by FDA in 1998, and it has been imitated by TIWA and mylan since 2013